974P First-in-human phase I dose finding study of INCB123667, a selective CDK2 inhibitor, in patients with advanced solid tumors. - Lorusso, D.; Simonelli, M.; Homicsko, K.; Colombo, I.; Kitano, S.; Cassier, P.; Robbrecht, D.G.; Italiano, A.; Pinato, D.J.; Hasegawa, K.; Bahleda, R.; Wang, E.; et al. (Annals of Oncology, 2025)